By Dr. Ajit Kumar, MD (Medicine) — Lifetime Member, Indian Medical Association. About the Author | Editorial Policy
Weight loss surgery dominated obesity treatment for over two decades. Surgeons could not keep up with demand. Hospital waiting lists stretched months long. Then, almost overnight, the operating rooms started getting quieter.
The reason is sitting in millions of medicine cabinets. GLP-1 drugs — Ozempic, Wegovy, Mounjaro, Zepbound — have surged so dramatically that bariatric surgery rates have dropped by 20 to 25 percent in just a few years. Patients who once had no choice but surgery now have another option. And they are taking it.
This is one of the biggest shifts in obesity treatment in modern medical history. But it comes with questions that doctors are only beginning to answer — and warnings that every patient considering either path needs to hear.
How Big Is the Shift?
Between 2022 and 2026, GLP-1 drug prescriptions doubled, then doubled again. A study tracking bariatric surgery candidates found that one in seven patients who would previously have gone straight to surgery were now choosing GLP-1 medication instead. Across major health systems, bariatric procedure volumes fell 20 to 25 percent — a number that would have been unthinkable just five years ago.
The appeal is straightforward. GLP-1 drugs deliver results that once required surgery: clinical trials show 15 to 20 percent body weight loss on average. They do it without anaesthesia, without a hospital stay, and without permanently altering the digestive system. For many patients, that trade-off is an easy decision.
Why Patients Are Choosing the Injection Over the Knife
The practical reasons are obvious. Surgery carries real risks — infection, complications, long recovery times. GLP-1 injections are taken at home, once a week, and can be stopped if side effects become a problem. Surgery cannot be undone.
Beyond the practical, there is also a psychological factor. For many people, the idea of a reversible treatment feels safer than an irreversible one. Even if surgery might offer stronger outcomes for certain patients, the ability to try medication first — and consider surgery later if needed — feels like a more measured approach to a lifelong condition.
What Experts Are Warning About
GLP-1 vs Bariatric Surgery: What the Research Shows
Long-term heart health. Mayo Clinic research suggests bariatric surgery may deliver greater cardiovascular benefits than GLP-1 medication alone — particularly for patients with existing heart disease or metabolic syndrome.
Muscle loss risk. GLP-1 drugs reduce appetite significantly. Without adequate protein intake, patients lose muscle alongside fat — slowing metabolism and weakening the body over time.
Metabolic depth. Surgery physically restructures the gut, triggering metabolic changes that go beyond weight loss — affecting insulin secretion, inflammation, and gut hormone signalling in ways medication may not fully replicate.
Combination approach. Johns Hopkins researchers note that some patients may benefit most from combining both — using GLP-1 drugs to lose initial weight before surgery, or surgery followed by GLP-1 therapy to maintain results.
The Muscle Loss Problem Nobody Talks About
One of the most underreported risks of GLP-1 therapy is what happens to muscle mass. When appetite drops sharply, total calorie intake falls — but so does protein intake. Muscle requires protein to maintain itself. Without enough, the body breaks down muscle tissue for energy.
Research suggests that up to 40 percent of weight lost on GLP-1 drugs can come from muscle rather than fat in patients who do not deliberately maintain high protein intake and resistance exercise. Doctors increasingly advise anyone on GLP-1 therapy to prioritise protein at every meal and incorporate strength training at least twice a week — not as optional extras, but as essential components of the treatment plan. For a detailed breakdown, read our comparison of Mounjaro vs Ozempic on muscle loss.
Who Should Still Consider Bariatric Surgery?
GLP-1 drugs are not appropriate for everyone, and bariatric surgery remains the better option in several well-defined clinical scenarios. Patients with a BMI above 50, severe sleep apnoea causing cardiac risk, or type 2 diabetes with very poor glycaemic control may achieve faster and more durable metabolic correction from surgical intervention than from medication alone.
Bariatric surgery also produces structural changes in gut anatomy that dramatically alter how hunger hormones like ghrelin are secreted. This means the hunger suppression after surgery is partly physiological and does not require ongoing drug costs — a significant consideration for patients in lower-income settings where GLP-1 medications are extremely expensive and not covered by insurance.
For younger patients with severe obesity who have co-morbidities like hypertension, non-alcoholic fatty liver disease, or polycystic ovarian syndrome, surgery may offer a one-time intervention that resolves multiple conditions simultaneously — something no drug currently replicates.
The Weight Regain Problem: What Happens When You Stop GLP-1 Drugs
One of the most important — and least discussed — aspects of GLP-1 therapy is what happens when treatment stops. Unlike surgery, which creates permanent anatomical changes, GLP-1 drugs only work while you are taking them. Clinical trials show that approximately 60 to 70 percent of weight lost on semaglutide or tirzepatide is regained within 12 months of stopping treatment.
This means GLP-1 therapy is effectively a lifelong commitment for most patients seeking sustained weight management. The drug must be continued indefinitely, at continuing cost, to maintain results. Understanding this before starting GLP-1 therapy is critical. The drugs are not a cure for obesity — they are a management tool.
Natural Metabolic Support: Where Berberine Fits In
For people who cannot yet access GLP-1 drugs — or who want to support their metabolic health naturally alongside any weight management approach — berberine has emerged as one of the most evidence-backed natural compounds available.
Berberine is a plant-derived compound that activates an enzyme called AMPK — sometimes called the body’s metabolic master switch. AMPK activation improves insulin sensitivity, supports healthy blood sugar regulation, and helps the body use energy more efficiently. Multiple clinical studies have shown berberine reduces fasting blood sugar, improves HbA1c, and supports weight management.
Support Your Metabolic Health Naturally
For metabolic support during weight loss, consider Berberine — a clinically studied plant compound that activates the body’s natural fat-burning and blood sugar regulation pathways. Check current price on Amazon.
Frequently Asked Questions
Can you have bariatric surgery after taking GLP-1 drugs?
Yes. GLP-1 drugs can be used to achieve 10 to 15 percent initial weight loss, which reduces surgical risk for patients with very high BMIs. GLP-1 therapy is typically paused before surgery and may be reintroduced afterward if weight regain occurs. Your bariatric surgeon should be involved in this decision from the start.
Do GLP-1 drugs work as well as weight loss surgery?
Surgery typically produces 30 to 40 percent total body weight loss that is largely durable. GLP-1 drugs average 15 to 20 percent with ongoing treatment required. For metabolic benefits like diabetes remission and cardiovascular risk reduction in severe cases, surgery maintains an advantage. For patients with BMI in the 30 to 40 range, GLP-1 drugs may provide equivalent benefit with significantly lower risk.
How much do GLP-1 drugs cost in India?
Monthly costs for GLP-1 medications typically range from Rs 10,000 to Rs 25,000 depending on the drug and dose. Bariatric surgery in India ranges from approximately Rs 2 to 4 lakh as a one-time cost, which may be more economically viable than decade-long GLP-1 therapy for some patients.
What happens to your weight when you stop taking Ozempic?
Clinical trials show that approximately 60 to 70 percent of weight lost on semaglutide is regained within 12 months of stopping the drug. GLP-1 drugs suppress appetite through a hormonal mechanism that reverses when the drug is discontinued. Most patients who want to maintain results need to continue treatment indefinitely, or transition to a sustained lifestyle programme specifically designed to preserve GLP-1-era weight loss.
What This Means for You
If you are managing your weight or considering treatment options, the single most important step is an honest conversation with your doctor. The right choice between GLP-1 medication, bariatric surgery, or a combined approach depends on your BMI, your cardiovascular history, your blood sugar levels, your access to ongoing medication costs, and your personal circumstances.
GLP-1 drugs are not a shortcut. Surgery is not an overreaction. Both are legitimate, evidence-based medical treatments for a serious metabolic disease. What matters is making an informed decision — one based on your specific situation, not on trends or headlines.
For the complete GLP-1 research breakdown including the surprising non-weight benefits, read our full article: Ozempic and Wegovy beyond weight loss — the 2026 research.
